Form 4: Immunome Inc. CEO Clay B. Siegall Increases Stake in Company

Clay B. Siegall, President and CEO of Immunome Inc., recently acquired additional shares of the company's common stock through open market purchases.

Summary

• On May 20, 2024, Clay B. Siegall purchased 79,566 shares of Immunome Inc. common stock at a weighted average price of $13.907 per share.
• The prices for these shares ranged from $13.77 to $13.99.
• Following this transaction, Siegall directly owns 399,202 shares.
• On May 21, 2024, Siegall purchased an additional 20,434 shares at a weighted average price of $13.7784 per share.
• The prices for these shares ranged from $13.62 to $13.99.
• Following this second transaction, Siegall directly owns 419,636 shares.
• These transactions were open market purchases.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the CEO's purchase of shares often indicates confidence in the company's future, but it's a single data point and doesn't guarantee success.

Positives

• The CEO's purchase of additional shares may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Key Dates